

Identification of potential key genes in gastric cancer using bioinformatics analysis

WEI WANG¹, YING HE², QI ZHAO³, XIAODONG ZHAO³ and ZHIHONG LI¹

¹Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700;

²Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075;

³Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R. China

Received October 5, 2019; Accepted January 27, 2020

DOI: 10.3892/br.2020.1281

Abstract. Gastric cancer (GC) is one of the most common types of cancer worldwide. Patients must be identified at an early stage of tumor progression for treatment to be effective. The aim of the present study was to identify potential biomarkers with diagnostic value in patients with GC. To examine potential therapeutic targets for GC, four Gene Expression Omnibus (GEO) datasets were downloaded and screened for differentially expressed genes (DEGs). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were subsequently performed to study the function and pathway enrichment of the identified DEGs. A protein-protein interaction (PPI) network was constructed. The CytoHubba plugin of Cytoscape was used to calculate the degree of connectivity of proteins in the PPI network, and the two genes with the highest degree of connectivity were selected for further analysis. Additionally, the two DEGs with the largest and smallest log Fold Change values were selected. These six key genes were further examined using Oncomine and the Kaplan-Meier plotter platform. A total of 99 upregulated and 172 downregulated genes common to all four GEO datasets were screened. The DEGs were primarily enriched in the Biological Process terms: 'extracellular matrix organization', 'collagen catabolic process' and 'cell adhesion'. These three KEGG pathways were significantly enriched in the categories: 'ECM-receptor interaction', 'protein digestion and absorption', and 'focal adhesion'. Based on Oncomine, expression of *ATP4A* and *ATP4B* were downregulated in GC, whereas expression of the other genes were all upregulated. The Kaplan-Meier plotter platform confirmed that upregulated expression of the identified key genes was significantly associated with worse overall survival of patients with GC. The

results of the present study suggest that *FNI*, *COL1A1*, *INHBA* and *CSTI* may be potential biomarkers and therapeutic targets for GC. Additional studies are required to explore the potential value of *ATP4A* and *ATP4B* in the treatment of GC.

Introduction

Gastric cancer (GC) is a malignant tumor that originates in the epithelium of the gastric mucosa and is one of the most common types of malignant tumors in the world (1). According to GLOBOCAN 2018, there were >1,000,000 new cases of GC and ~783,000 deaths in 2018, thus making it the cancer type with the fifth highest incidence rate and the third highest mortality in the world (2). The poor five-year survival rate of GC is primarily due the advanced stage of gastric tumors at the initial diagnosis in the majority of patients, and thus limits treatment opportunities (3). According to the Cancer Staging Manual, 8th edition, of the American Joint Committee on Cancer, only 30% of GC cases are diagnosed prior to metastasis, and the five-year survival for pathological Tumor-Node-Metastasis stage groups are between 68-80% for stage I, 46-60% for stage II, 8-30% for stage III and 5% for stage IV (4). Therefore, identifying potential biomarkers for patients with early GC is critical for improving patient outcomes.

In recent years, a variety of bioinformatics methods have contributed greatly to the discovery of biomarkers associated with tumor development, diagnosis and prognosis (5-8). The combined use of multiple databases of biological information for the analysis of cancer has also yielded certain breakthroughs. Yong *et al* (9) used Gene Expression Omnibus (GEO), Oncomine, Search Tool for Recurring Instances of Neighbouring Genes (STRING) and other databases for bioinformatic analysis, and concluded that *PPP2CA* may function as an oncogene and a prognostic biomarker or therapeutic target in the progression of colorectal cancer. Troiano *et al* (10) used the GEO database and Oncomine to examine the expression of *BIRC5*/Survivin in oral squamous cell carcinoma and showed that Survivin expression was upregulated compared with non-cancerous tissue. In addition, immunohistochemistry staining showed that cytoplasmic expression of Survivin was associated with poor overall survival in patients with oral squamous cell carcinoma. It may

Correspondence to: Dr Zhihong Li, Department of Gastroenterology, Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang Street, Beijing 100700, P.R. China
E-mail: lzhlshn@sina.com

Key words: gastric cancer, differentially expressed genes, key genes, bioinformatics analysis, diagnosis

be beneficial to use multiple datasets and analysis tools to determine the potential mechanisms underlying development and progression of GC, and to identify potentially novel and specific diagnostic biomarkers for early detection of GC to improve the survival of patients.

In the present study, the expression profiles from four datasets (GSE13911, GSE19826, GSE54129 and GSE118916) in human GC and normal gastric tissue samples were obtained from the GEO database and analyzed to identify differentially expressed genes (DEGs). Gene Ontology (GO) and pathway enrichment analysis were performed to identify the biological functions and pathways of the DEGs. STRING and Cytoscape were used to construct a protein-protein interaction (PPI) network, and a total of six key genes were selected from the PPI network and DEGs. The value of the key genes was validated using the Oncomine and Kaplan-Meier platforms to further increase the reliability of the results and confirm the prognostic value of the key genes.

Materials and methods

Microarray data. The key word ‘gastric cancer’ was searched in the GEO database (ncbi.nlm.nih.gov/geo/), and a total of 9,224 datasets on human GC were retrieved. In the present study, four gene expression profiles from the GEO database were used, as they have not been studied together previously. The four datasets were: GSE13911 (11), GSE19826 (12), GSE54129 and GSE118916 (13). Among these, GSE13911, GSE19826 and GSE54129 were based on the GPL570 platform [(HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array]. GSE118916 was based on the GPL15207 platform [(PrimeView) Affymetrix Human Gene Expression Array].

Identification of DEGs. DEGs between GC samples and normal controls were identified using the GEO2R online analysis tool (ncbi.nlm.nih.gov/geo/geo2r/); $|\log FC| \geq 1.0$ and corrected $P < 0.05$ were used as the cutoff criteria. The common DEGs of the four gene expression profiles were screened using Wayne analysis in Funrich (funrich.org/).

GO and KEGG enrichment analyses of DEGs. After obtaining the common DEGs, GO (14,15) and KEGG (16) analyses of the DEGs were performed using the Database for Annotation Visualization and Integrated Discovery (DAVID) online tool (17,18), with $P < 0.01$ used as the threshold for significance. GO was used to identify the enrichment functions of three independent categories of genes; biological process (BP), cellular component (CC) and molecular function (MF). KEGG was used to search for the pathways associated with the identified genes (19). Only the top 10 BP, CC and MF terms, and the KEGG pathway with the smallest P-value were selected for further examination in the present study. The figures were generated using the OmicShare tools (omicshare.com/tools/), a free online platform for data analysis.

PPI network construction. To explore the interaction between DEGs, the DEGs were analyzed using STRING (20) to generate a PPI network. PPI pairs with a combined score > 0.4 were extracted, and disconnected nodes in the network were hidden. Subsequently, the PPI network was visualized using

Table I. Information for four gene expression profiles from Gene Expression Omnibus.

Dataset ID	Gastric cancer	Normal	Total Number	Platform
GSE13911	38	31	69	GPL570
GSE19826	12	15	27	GPL570
GSE54129	111	21	132	GPL570
GSE118916	15	15	30	GPL15207

Cytoscape (21) and the degree of each protein node was calculated using the cytoHubba (22) plug-in in Cytoscape.

Identification of key genes. The two genes with the highest degree of connectivity in the PPI network, the two genes with the largest logFC values and the two genes with the smallest logFC among the shared DEGs were selected and considered key genes.

Analysis of key genes in Oncomine. The Oncomine database (oncomine.org/) was used to explore the mRNA expression differences of six key genes between GC and normal gastric tissue. Oncomine is a chip-based gene database and integrated data mining online cancer microarray database designed to facilitate the discovery of novel biomarkers from genome-wide expression analysis (23).

Survival analysis of key genes. The Kaplan-Meier plotter (24) is an online tool that can assess the effect of 54,000 genes on survival in 21 types of cancer. The largest datasets include breast ($n=6,234$), ovarian ($n=2,190$), lung ($n=3,452$) and gastric cancer ($n=1,440$) cancer. The primary purpose of the tool is to discover and validate biomarkers for survival. Online survival analysis of the selected key genes based on the GC database was performed using Kaplan-Meier Plotter. The hazard ratio (HR) with 95% confidence intervals (CIs) and log-rank P-values were calculated.

Results

Identification of DEGs. GSE13911 includes 38 GC samples and 31 normal samples, GSE19826 contains 12 GC samples and 15 normal samples, GSE54129 contains 111 GC samples and 21 normal samples, and GSE118916 contains 15 GC samples and 15 normal samples (Table I). In GSE13911, there are 26 intestinal, 4 mixed, 6 diffuse and 2 unclassified gastric carcinoma tissues, as well as 31 normal adjacent tissues. Unfortunately, information on the histological subtypes were not available in the other datasets. In the datasets, 1,001 upregulated and 2,304 downregulated DEGs were identified in GSE13911, 407 upregulated and 753 downregulated DEGs were identified in GSE19826, 1,852 upregulated and 2,083 downregulated DEGs were identified in GSE54129, and 977 upregulated and 903 downregulated DEGs were identified in GSE118916. Wayne analysis identified 99 common upregulated genes and 172 common downregulated genes were obtained from the 4 datasets (Table II; Fig. 1).

Table II. The differentially expressed genes identified from the four gene expression profiles, between gastric cancer and normal tissues.

Differentially expressed genes	Gene terms
Upregulated	INHBA CST1 COL11A1 FAP COL10A1 FNDC1 COL8A1 SERPINH1 CDH3 THBS2 CLDN1 TNFRSF11B SPP1 COL1A2 SFRP4 SULF1 CPXM1 BMP1 MFAP2 COL1A1 CTHRC1 BGN RARRES1 IGF2BP3 THBS4 COL6A3 SRPX2 OSR2 HOXB7 TIMP1 ASPN THY1 FKBP10 PRRX1 SDS APOE PMEPA1 COL12A1 GPNMB FBN1 ADAM12 C3 APOC1 COL5A1 SPARC EPHB2 NID2 CMTM3 PLEKHO1 TNFRSF10B EHD2 FN1 MMP11 COCH AMIGO2 COL5A2 OLFML2B KLHL23 SPOCK1 CDH11 TWIST1 RAB31 SULF2 FGD6 VCAN ITGBL1 PCOLCE HAVCR2 THBS1 DNM1 IGFBP7 PLAUI TMEM158 COL3A1 FLNA EDNRA LEF1 LIPG FZD2 GXYLT2 S100A10 LGALS1 NRP2 SIRPA ANTXR1 CD9 LIF COL4A2 TGM2 COL6A1 PDPN KCNJ8 ACTN1 GPR161 ZAK RCN3 BAG2 BHLHE40 COL4A1
Downregulated	ATP4A ATP4B KCNE2 AQP4 GIF LIPF GKN1 GKN2 DPCR1 PGC SOSTDC1 ESRRG MUC6 SST FBP2 CPA2 VSIG1 CXCL17 PDIA2 CCKBR TMED6 CHGA TFF2 PSCA FUT9 CA9 SCNN1G GUCA2B C16orf89 SLC26A9 KLK11 CWH43 DNER PSAPL1 CNTN3 ALDH3A1 GATA5 SCGB2A1 UGT2B15 RDH12 CLIC6 NRG4 CLDN18 CAPN9 SLC16A7 SSTR1 FBXL13 TCN1 VSIG2 AKR1B10 B3GNT6 FOLR1 MUM1L1 CHGB MAL TRIM50 AKR7A3 KIAA1324 PAIP2B SULT2A1 PTPRZ1 ARX LIFR ALDH1A1 HYAL1 BEX5 CA2 CYP2C18 ME1 SCNN1B ADH7 GCNT2 ACER2 FMO5 HPGD RASSF6 TFF1 TMEM171 CA4 KCNJ16 LDHD KCNJ15 GABRB3 HOMER2 TMPRSS2 LYPD6B KLHDC7A ARHGAP42 PLAC8 IGFBP2 CAPN13 SYTL5 PDGFD RNASE1 RORC CYP2C9 EPN3 PBLD METTL7A ZBTB7C UBL3 SH3RF2 RNASE4 ARHGEF37 ALDH6A1 RAB27B SULT1B1 PKIB PXMP2 GPRC5C RIMBP2 ATP8A1 FAM20A PIGR GOLM1 CYP3A5 FAM46C C9orf152 COBL1 FA2H SORBS2 DGKD SGK2 TMEM220 ANG PLLP MYCN C1orf116 FGD4 SLC41A2 ADAM28 MAGI1 GRAMD1C IQGAP2 GULP1 SYTL2 DHRS7 OASL RNF128 DBT ELL2 RAB27A NOSTRIN NEDD4L PPFIBP2 AKR1C3 PELI2 SMPD3 PTPRN2 RASEF TMEM92 ABCC5 GALNT12 LMO4 NTN4 TMEM116 ID4 ELOVL6 ALDOB EPB41L4B CD36 GALNT5 SH3BGR12 MAGI3 MICALL1 HIPK2 MAOA WWC1 SLC7A8 CDC14B FAM107B SUCLG2

Upregulated genes are listed from largest to smallest fold change values. Downregulated genes are listed from smallest to largest fold change values.




Figure 1. Venn diagram of shared differentially expressed genes. (A) Upregulated and (B) downregulated genes from four gene expression profiles.

GO and KEGG pathway enrichment analyses of DEGs. GO and KEGG pathway enrichment analyses of the DEGs was performed using the online tool DAVID, and the results are presented in Table III. GO analysis showed that in BP, the DEGs were primarily enriched for the GO terms: ‘extracellular

matrix organization’, ‘collagen catabolic process’, ‘cell adhesion’, ‘collagen fibril organization’ and ‘digestion’ (Table III; Fig. 2A). CC analysis revealed that the DEGs were significantly enriched for the terms: ‘extracellular space’, ‘extracellular matrix’, ‘extracellular exosome’, ‘extracellular region’ and

Table III. GO term and KEGG pathway enrichment analyses of the 271 differentially expressed genes.

Category	Term	Description	Count	P-Value
BP term	GO:0030198	Extracellular matrix organization	23	1.28×10^{-13}
BP term	GO:0030574	Collagen catabolic process	14	7.06×10^{-12}
BP term	GO:0007155	cell adhesion	30	3.59×10^{-11}
BP term	GO:0030199	Collagen fibril organization	9	7.87×10^{-08}
BP term	GO:0007586	Digestion	10	3.19×10^{-07}
BP term	GO:0035987	Endodermal cell differentiation	7	2.13×10^{-06}
BP term	GO:0001501	Skeletal system development	11	3.42×10^{-05}
BP term	GO:0008202	Steroid metabolic process	7	3.60×10^{-05}
BP term	GO:0071230	Cellular response to amino acid stimulus	7	6.04×10^{-05}
BP term	GO:0006805	Xenobiotic metabolic process	8	1.45×10^{-04}
BP term	GO:0042060	Wound healing	8	1.70×10^{-04}
BP term	GO:0006081	Cellular aldehyde metabolic process	4	4.70×10^{-04}
BP term	GO:0030277	Maintenance of gastrointestinal epithelium	4	6.20×10^{-04}
BP term	GO:0010107	Potassium ion import	5	6.98×10^{-04}
BP term	GO:0007584	Response to nutrient	7	7.50×10^{-04}
BP term	GO:0002576	Platelet degranulation	8	7.99×10^{-04}
BP term	GO:0060021	Palate development	7	8.64×10^{-04}
BP term	GO:0010812	Negative regulation of cell-substrate adhesion	4	0.001003
BP term	GO:0001503	Ossification	7	0.001131
BP term	GO:0030168	Platelet activation	8	0.001523
BP term	GO:0051216	Cartilage development	6	0.001703
BP term	GO:0010628	Positive regulation of gene expression	12	0.001721
BP term	GO:0001523	Retinoid metabolic process	6	0.001977
BP term	GO:0016525	Negative regulation of angiogenesis	6	0.002125
BP term	GO:0055114	Oxidation-reduction process	19	0.002857
BP term	GO:0032964	Collagen biosynthetic process	3	0.003084
BP term	GO:0008284	Positive regulation of cell proliferation	16	0.003752
BP term	GO:0001649	Osteoblast differentiation	7	0.004274
BP term	GO:0022617	Extracellular matrix disassembly	6	0.005144
BP term	GO:0071711	Basement membrane organization	3	0.005647
BP term	GO:0050891	Multicellular organismal water homeostasis	3	0.005647
BP term	GO:0001525	Angiogenesis	10	0.005716
BP term	GO:0042476	Odontogenesis	4	0.007007
BP term	GO:0010575	Positive regulation of vascular endothelial growth factor production	4	0.007007
BP term	GO:0050909	Sensory perception of taste	4	0.008568
BP term	GO:0001937	Negative regulation of endothelial cell proliferation	4	0.008568
BP term	GO:0040037	Negative regulation of fibroblast growth factor receptor signaling pathway	3	0.008901
BP term	GO:0042572	Retinol metabolic process	4	0.009418
CC term	GO:0005615	Extracellular space	63	9.65×10^{-17}
CC term	GO:0031012	Extracellular matrix	28	2.46×10^{-14}
CC term	GO:0070062	Extracellular exosome	87	1.68×10^{-12}
CC term	GO:0005576	Extracellular region	61	4.86×10^{-12}
CC term	GO:0005788	Endoplasmic reticulum lumen	20	4.73×10^{-11}
CC term	GO:0005581	Collagen trimer	15	5.56×10^{-11}
CC term	GO:0005604	Basement membrane	9	1.82×10^{-05}
CC term	GO:0005578	Proteinaceous extracellular matrix	22	3.57×10^{-10}
CC term	GO:0016324	Apical plasma membrane	16	2.29×10^{-05}
CC term	GO:0009986	Cell surface	20	3.51×10^{-04}
CC term	GO:0005887	Integral component of plasma membrane	34	0.004256
CC term	GO:0005886	Plasma membrane	79	0.004569

Table III. Continued.

Category	Term	Description	Count	P-Value
CC term	GO:0030141	Secretory granule	6	0.004319
CC term	GO:0031093	Platelet alpha granule lumen	5	0.008125
CC term	GO:0031090	Organelle membrane	6	0.008522
MF term	GO:0048407	Platelet-derived growth factor binding	6	2.55x10 ⁻⁰⁷
MF term	GO:0005518	Collagen binding	8	2.37x10 ⁻⁰⁵
MF term	GO:0050840	Extracellular matrix binding	6	3.05x10 ⁻⁰⁵
MF term	GO:0005242	Inward rectifier potassium channel activity	4	0.002802
MF term	GO:0046332	SMAD binding	5	0.003328
MF term	GO:0005201	Extracellular matrix structural constituent	12	2.77x10 ⁻⁰⁹
MF term	GO:0001758	Retinal dehydrogenase activity	3	0.004132
MF term	GO:0005178	Integrin binding	11	2.77x10 ⁻⁰⁶
MF term	GO:0005509	Calcium ion binding	27	1.47x10 ⁻⁰⁵
MF term	GO:0008201	Heparin binding	12	2.07x10 ⁻⁰⁵
MF term	GO:0016491	Oxidoreductase activity	9	0.008547
MF term	GO:0008083	Growth factor activity	8	0.009105
KEGG pathway	hsa04512	ECM-receptor interaction	16	5.16x10 ⁻¹¹
KEGG pathway	hsa04974	Protein digestion and absorption	14	7.73x10 ⁻⁰⁹
KEGG pathway	hsa04510	Focal adhesion	18	2.67x10 ⁻⁰⁷
KEGG pathway	hsa05146	Amoebiasis	10	1.63x10 ⁻⁰⁴
KEGG pathway	hsa04971	Gastric acid secretion	8	4.23x10 ⁻⁰⁴
KEGG pathway	hsa04151	PI3K-Akt signaling pathway	17	7.35x10 ⁻⁰⁴
KEGG pathway	hsa00830	Retinol metabolism	7	0.00124
KEGG pathway	hsa00982	Drug metabolism-cytochrome P450	7	0.001703
KEGG pathway	hsa00980	Metabolism of xenobiotics by cytochrome P450	7	0.002628
KEGG pathway	hsa05204	Chemical carcinogenesis	7	0.003889

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological processes; CC, cellular component; MF, molecular function.

'endoplasmic reticulum lumen' (Table III; Fig. 2B). For MF, the DEGs were enriched for the GO terms: 'platelet-derived growth factor binding', 'collagen binding', 'extracellular matrix binding', 'inward rectifier potassium channel activity' and 'SMAD binding' (Table III; Fig. 2C). According to KEGG pathway analysis, the DEGs were primarily enriched for the pathway terms: 'ECM-receptor interaction', 'protein digestion and absorption', 'focal adhesion', 'amoebiasis' and 'gastric acid secretion' (Table III; Fig. 2D).

PPI network construction. Based on the STRING prediction results, a PPI network with 211 nodes and 741 sides was constructed in Cytoscape (Fig. 3), and the number of segments connected to each gene in the figure represents its degree.

Identification of six key genes. The two genes with the most nodes were *FN1* and *COL1A1*. In the PPI network, *FN1* was the most prominent, with the highest degree of connectivity at 52. The degree of connectivity of *COL1A1* is 43 (Table IV). Expression of these two genes is upregulated in GC tissues. Additionally, of those DEGs shared among the four gene expression profiles, the two DEGs with the largest logFC and the two DEGs with the smallest logFC values were selected. The higher the logFC in the upregulated DEGs, the greater

Table IV. The 10 genes with the largest degree of connectivity in the protein-protein-interaction network.

Rank	Gene	Degree
1	FN1	52
2	COL1A1	43
3	COL1A2	38
4	COL3A1	37
5	FBN1	35
6	BGN	32
6	COL5A2	32
8	TIMP1	31
9	SPARC	30
10	THBS2	28

the increase in expression of the gene. Similarly, the lower the logFC values in the downregulated DEGs, the greater the decrease in expression of the gene. When sorting DEGs according to logFC, the logFC of GSE19826 was used as the standard, as chip GSE19826 represented a homogenous cancer




Figure 2. Gene Ontology terms and KEGG pathway enrichment analyses of 271 differentially expressed genes. Top 10 terms of enrichment for (A) BP, (B) CC and (C) MF. (D) Top 10 enriched KEGG pathways. KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cellular component; MF, molecular function.

tissue population at each Tumor-Node-Metastasis stage (25), which increases the accuracy of the expression profile (Table V). The two DEGs with the largest logFC values were *INHBA* (logFC=4.35) and *CST1* (logFC=4.18) (Table VI). The two DEGs with the smallest logFC values were *ATP4A* (logFC=-6.46) and *ATP4B* (logFC=-5.91) (Table VII). Therefore, these six genes were selected as key genes.

Analysis of the six key genes in Oncomine. The Oncomine database was used to confirm the expression of the six key genes in 20 different types of cancer. The results showed that there were statistically significant differences in their expression. In the Oncomine database, there were no studies showing low expression of *FNI*, *COL1A1*, *INHBA* or *CST1* in GC, but there were six, eight, seven and four studies showing increased

expression, respectively. For *ATP4A* and *ATP4B*, the reverse was observed with no studies showing high expression, but seven and six studies, respectively, showing decreased expression (Fig. 4).

After comparing the expression levels of these six genes in cancerous and normal gastric tissue, the expression levels of *FNI*, *COL1A1*, *INHBA* and *CST1* in GC tissues were significantly higher compared with the control group, and the expression levels of *ATP4A* and *ATP4B* in GC tissues were significantly lower compared with the control group (Table VIII; Fig. 5).

In addition, meta-analyses of the six key genes in GC in the Oncomine database also supported the findings that expression of *FNI*, *COL1A1*, *INHBA* and *CST1* is upregulated in GC, whereas expression of *ATP4A* and *ATP4B* is downregulated in GC (11,12,26-28). The studies and references involved are




Figure 3. Protein-protein interaction network of differentially expressed genes. Red indicates upregulated genes, and green represents downregulated genes.

shown in Fig. 6. In the meta-analyses, $P=0.000$, $FC \geq 2.0$ and gene rank ≤ 300 were selected as the cutoff criteria.

Survival analysis of the six key genes. To identify the prognostic value of the six potential key genes, overall survival curves based on differential expression of the six key genes were plotted using Kaplan-Meier plotter (Fig. 7). There were 1,440 patients with GC on the Kaplan-Meier plotter platform who were suitable for the analysis of overall survival. The curves indicate that overexpression of the six key genes is significantly associated with decreased overall survival times of patients with GC. However, it is worth noting that *ATP4A* and *ATP4B* were significantly downregulated in GC samples in the present study.

Discussion

GC is a complex heterogeneous disease with high incidence and mortality rates, and poses a serious threat to afflicted patients. Therefore, it is important to identify biomarkers

that are meaningful for both diagnostic and prognostic assessment (29).

In the present study, 271 DEGs were screened, including 99 upregulated and 172 downregulated genes, by analyzing four gene expression profiles containing a combined 176 GC tissue samples and 82 normal gastric tissue samples. Of the causes of cancer-associated deaths, 90% are the result of metastasis (30). In the present study, GO enrichment results showed that the occurrence and development of GC was closely associated with metastasis. GO analysis indicated that DEGs were primarily associated with extracellular matrix organization, collagen catabolic process and cell adhesion. Collagen is the primary component of the extracellular matrix and of the interstitial microenvironment. Collagen can provide a scaffold for tumor cell growth and induce migration of tumor cells (31,32). There is evidence that collagen synthesis increases in the presence of a gastric tumor (33). Zhou *et al* (32) reported that collagen components are quantitatively and qualitatively reorganized in the tumor microenvironment of GC, and collagen width was identified

Table V. The expression data from GSE19826 in gastric cancer.

Tissue type	Accession no.	Title	Stage
Noncancer tissue	GSM495051	CB2008210-1N	n/a
Gastric cancer tissue	GSM495052	CB2008210-1T	II
Noncancer tissue	GSM495053	CB2008210-2N	n/a
Gastric cancer tissue	GSM495054	CB2008210-2T	IV
Noncancer tissue	GSM495055	CB2008210-3N	n/a
Gastric cancer tissue	GSM495056	CB2008210-3T	I
Noncancer tissue	GSM495057	CB2008210-4N	n/a
Gastric cancer tissue	GSM495058	CB2008210-4T	II
Noncancer tissue	GSM495059	CB2008210-5N	n/a
Gastric cancer tissue	GSM495060	CB2008210-5T	III
Noncancer tissue	GSM495061	CB2008210-6N	n/a
Gastric cancer tissue	GSM495062	CB2008210-6T	IV
Noncancer tissue	GSM495063	CB2008210-7N	n/a
Gastric cancer tissue	GSM495064	CB2008210-7T	IV
Noncancer tissue	GSM495065	CB2008210-9N	n/a
Gastric cancer tissue	GSM495066	CB2008210-9T	III
Noncancer tissue	GSM495067	CB2008210-12N	n/a
Gastric cancer tissue	GSM495068	CB2008210-12T	II
Noncancer tissue	GSM495069	CB2008210-13N	n/a
Gastric cancer tissue	GSM495070	CB2008210-13T	I
Noncancer tissue	GSM495071	CB2008210-14N	n/a
Gastric cancer tissue	GSM495072	CB2008210-14T	III
Noncancer tissue	GSM495073	CB2008210-15N	n/a
Gastric cancer tissue	GSM495074	CB2008210-15T	I
Normal gastric tissue	GSM495075	CB2008210-3C	n/a
Normal gastric tissue	GSM495076	CB2008210-5C	n/a
Normal gastric tissue	GSM495077	CB2008210-9C	n/a

Table VI. The 10 genes with the largest logFC values in GSE19826.

Rank	Name	LogFC
1	INHBA	4.35
2	CST1	4.18
3	COL11A1	4.11
4	FAP	3.91
5	COL10A1	3.72
6	FNDC1	3.27
6	COL8A1	3.17
8	SERPINH1	2.97
9	CDH3	2.95
10	THBS2	2.94

FC, fold change.

Table VII. The 10 genes with the smallest logFC values in GSE19826.

Rank	Name	LogFC
1	ATP4A	-6.46
2	ATP4B	-5.91
3	KCNE2	-5.88
4	AQP4	-5.81
5	GIF	-5.75
6	LIPF	-5.53
6	CHIA	-5.51
8	GKN1	-5.49
9	GKN2	-5.44
10	DPCR1	-4.83

FC, fold change.

as a useful prognostic indicator for GC (32). In addition, studies have shown that changes in cell-cell adhesion and cell-matrix adhesion can promote cancer cell metastasis (34). MF analysis showed that the DEGs were significantly

enriched in platelet-derived growth factor binding. It has been demonstrated that inhibition of platelet-derived growth factor receptor- α can reduce the proliferation of gastrointestinal stromal tumor cells with mutant v-kit Hardy-Zuckerman 4




Figure 4. mRNA expression of the six key genes in 20 different types of cancer. Cell color is determined by the best gene rank percentile for the analyses within the cell.

feline sarcoma viral oncogene homolog (KIT) by affecting the KIT-dependent transcription factor ETV1 (35).

KEGG pathway analysis showed that the DEGs were primarily enriched in ECM-receptor interaction, protein digestion and absorption, and focal adhesion. ECM-receptor interaction serves a vital role in several types of cancer (36-38). The interaction between membrane receptors of tumor cells and ECM proteins serve an important role in tumor invasion and metastasis (39), and ECM-receptor interaction serve a crucial role in the process of tumor shedding, adhesion, degradation, movement and hyperplasia (38). In addition, the non-steroidal anti-inflammatory drug celecoxib may exhibit anti-GC effects by inhibiting the expression of various proteins and inhibiting leukocyte transendothelial migration and focal adhesion (40), which provides a possible mechanism for future investigations of the role of focal adhesion in GC and developing new anti-GC drugs.

The degree of connectivity of a gene in a PPI network reflects its association with GC. The greater the connectivity, the closer a gene is to the disease mechanism. The logFC values of DEGs reflects the level of up or downregulation of the gene. The higher the logFC values in the upregulated DEGs, the greater the degree of upregulation of the gene, and the lower the logFC values in the downregulated DEGs, the greater the degree of downregulation (41-43). Thus it was hypothesized that the DEGs with the highest and lowest logFC values would be the genes most closely associated with disease mechanisms.

In the present study, the two genes with the highest degree of connectivity in the PPI network, and the two DEGs with the largest and smallest logFC values, were all selected as key genes. These were *FNI*, *COL1A1*, *INHBA*, *CSTI*, *ATP4A* and

ATP4B. These six key genes were verified in the Oncomine database. Expression of *FNI*, *COL1A1*, *INHBA* and *CSTI* were upregulated in GC, and expression of *ATP4A* and *ATP4B* were downregulated, consistent with the results obtained from analysis of the GEO datasets. Furthermore, survival analysis showed that upregulation of the six key genes was significantly associated with worse overall survival, and downregulation of *ATP4A* and *ATP4B* expression predicted a more favorable prognosis for patients with GC, providing novel insights into potential GC treatment strategies.

FNI was the gene with the highest degree of connectivity. It is expressed in a wide range of healthy plasmalemmas, lamina propria mucosae and smooth-muscle cell layers, and it is involved in a variety of cellular processes including embryogenesis, blood coagulation, wound healing, host defense and metastasis (44). As a glycoprotein involved in cell adhesion and migratory processes, *FNI* is hypothesized to be associated with signaling pathways associated with cancer (13). Expression of *FNI* is significantly increased in anti-chemotherapy osteosarcoma cell lines and tissues, and is associated with a poor prognosis (45). Knockdown of *FNI* gene expression results in reduced cell proliferation, increased cellular senescence and apoptosis, and reduced migration and invasion, by blocking the activation of the PI3K/AKT signaling pathway (46). Furthermore, downregulation of *FNI* inhibits proliferation, migration and invasion, and thus reduces progression of colorectal cancer (47). The results of the present study suggest that *FNI* may be a potential biomarker and therapeutic target for diagnosis and treatment of GC, consistent with previous studies (13,48,49), and thus further confirming the significance of *FNI* in GC.

COL1A1 is one of the most important components of the ECM, and it is highly expressed in most connective tissues and various human solid tumors (50). It is also the primary component of type I collagen, which serves a key role in tumor cell adhesion and invasion (51). A mechanistic study revealed that *COL1A1* and *COL1A2* affects angiogenesis in GC, and their expression is also significantly associated with progression of GC (52). In addition, Zhang *et al* (53) further confirmed that overexpression of *COL1A1* promoted GC cell proliferation *in vitro*. These previous studies support the use of *COL1A1* as a key potential GC biomarker in the present study.

INHBA is a member of the transforming growth factor- β (TGF- β) superfamily, which is closely associated with tumor proliferation and expression is upregulated in lung cancer (54), GC (12) and colon cancer (55), where *INHBA* expression is closely associated with their prognosis. In a study of GC, Chen *et al* (56) found that *INHBA* gene silencing reduced migration and invasion of GC cells by blocking the activation of the TGF- β signaling pathway. They suggested that *INHBA* was a potential target for GC therapy (56). Another study showed that *INHBA* mRNA expression in GC may be a useful prognostic biomarker for patients with stage II or III GC who receive adjuvant chemotherapy with S-1 (57). The results of the present study support the conclusions drawn in these previous studies.

Cystatin SN (*CSTI*) is a member of the type 2 cystatin superfamily, the primary role of which is to limit the proteolytic activity of cysteine proteases (58). The dysregulated expression of *CSTI* is hypothesized to be involved in several types of

Table VIII. Additional information for the six key genes shown in Figure 5.

Author, year	Gene	Normal tissue samples	Gastric cancer samples	P-value	Fold Change	Published journal	(Refs.)
Chen <i>et al</i> , 2003	FN1	28	8	5.73×10^{-14}	7.441	Molecular Biology of The Cell	(26)
Cui <i>et al</i> , 2011	COL1A1	80	80	1.81×10^{-15}	3.201	Nucleic Acids Research	(28)
Cui <i>et al</i> , 2011	INHBA	80	80	5.17×10^{-13}	3.043	Nucleic Acids Research	(28)
Cho <i>et al</i> , 2011	CST1	19	31	3.17×10^{-13}	21.525	Clinical Cancer Research	(27)
Cho <i>et al</i> , 2011	ATP4A	19	20	4.73×10^{-17}	-100.911	Clinical Cancer Research	(27)
D'Errico <i>et al</i> , 2009	ATP4B	31	26	6.15×10^{-19}	-246.630	European Journal of Cancer	(11)




Figure 5. Expression of six key genes in different gastric cancer gene chips in Oncomine. $P < 0.0001$ and a $|\text{fold change}| > 2$ were used as the threshold. Comparison of mRNA expression in cancerous vs. normal gastric tissue. (A) *FN1*, (B) *COL1A1*, (C) *INHBA*, (D) *CST1*, (E) *ATP4A* and (F) *ATP4B*.

cancer, including cholangiocarcinoma (59), breast cancer (58), GC (60) and colorectal cancer (61). *CST1* prevents cell aging and promotes cancer development by affecting the activity of cathepsin B (62). However, *CST1* has not been analyzed using

bioinformatics for survival prognosis in GC, to the best of our knowledge. Using multiple databases, the present study is the first to validate *CST1* as a novel prognostic biomarker and a potential therapeutic target for treatment of GC.




Figure 6. Meta-analyses of the six key genes in gastric cancer in Oncomine. (A) *FN1*, (B) *COL1A1*, (C) *INHBA*, (D) *CST1*, (E) *ATP4A* and (F) *ATP4B*.

ATP4A encodes the α subunit and *ATP4B* encodes the β subunit of the gastric H⁺, K⁺-ATPase, respectively. They regulate gastric acid secretion and, as a result, are targets for acid reduction (63). Fei *et al* (64) found that expression

of *ATP4A* and *ATP4B* were significantly downregulated in patients with GC, but their expression was not significantly correlated with overall survival (64). In the present study, downregulation of *ATP4A* and *ATP4B* expression




Figure 7. Kaplan-Meier overall survival analyses of patients with gastric cancer based on expression of the six key genes. (A) FN1, (B) COL1A1, (C) INHBA, (D) CST1, (E) ATP4A, (F) ATP4B. HR, hazard ratio.

was associated with favorable overall survival in patients with GC. Downregulation of *ATP4A* and *ATP4B* mRNA expression in GC tissue is associated with the development of GC (65). Correa's Cascade is inversely associated with gastric acid secretion rate, the downregulation of *ATP4A* and *ATP4B* mRNA expression begins in the early stages of gastric mucosal lesions, and the expression of both is gradually decreased as Correa's cascade progresses (66). In addition, *Helicobacter pylori* (*H. pylori*) inhibits parietal

acid secretion by downregulating the expression of *ATP4A* and *ATP4B* in gastric parietal cells prior to the formation of GC, suggesting that *H. pylori* is closely associated with the development of GC (67). Thus, it was hypothesized that *ATP4A* and *ATP4B* may inhibit the formation of GC. Survival analysis showed that *ATP4A* and *ATP4B* in GC are adverse prognostic factors for patients with GC, suggesting that upregulation is associated with progression of GC. However, studies have reported that the expression of *ATP4A*

and *ATP4B* is not regulated by *H. pylori* in GC (68-70). Other studies have shown significant decreases in the abundance of *Helicobacter* and *Neisseria*, and significant increases in *Achromobacter*, *Citrobacter*, *Phyllobacterium*, *Clostridium*, *Rhodococcus* and *Lactobacillus* in gastric carcinoma in comparison with chronic gastritis (71,72). Additionally, the gastric microbiota composition in patients with gastric carcinoma is significantly different compared with patients with chronic gastritis (71). Therefore, it was hypothesized that the formation of an altered gastric microbiota composition may result in the expression of *ATP4A* and *ATP4B* to be passively upregulated as GC progresses. Further research is required to more accurately determine the biological function of *ATP4A* and *ATP4B* in GC.

Although several genes were identified as promising diagnostic and prognostic biomarkers for GC, the present study has the following limitations. First, the present study lacked experimental and clinical validation. Second, the possibility that different histological types may affect the accuracy of results cannot be eliminated. Thus, future bioinformatics analysis should be designed such that samples can be stratified by histological type. Finally, the sample size was relatively small for the RNA-Seq experiments, which may result in inaccuracies or results which are not completely representative of the wider populace. Therefore, it is necessary to use larger samples to perform bioinformatics analysis, and further experimental and clinical studies are required.

In conclusion, the present study used bioinformatics to analyze biological processes and signaling pathways closely associated with GC occurrence and development and identified *FN1*, *COL1A1*, *INHBA* and *CST1* as promising diagnostic and prognostic biomarkers for GC patients. Additionally, the results of the survival analysis of *ATP4A* and *ATP4B* were inconsistent with other international studies. Therefore, further studies are required to assess the effects of *ATP4A* and *ATP4B* on GC initiation and development. Furthermore, experimental and clinical studies are required to validate the findings of the present study and determine the potential clinical value of these potential biomarkers.

Acknowledgements

Not applicable.

Funding

The present study was funded by the National Key R&D Program of China (grant nos. 2018YFC1704100 and 2018YFC1704106).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

WW and YH conceived of and designed the study. YH and QZ performed the bioinformatics analysis and analyzed the data. WW and QZ wrote the manuscript. WW and ZL revised

the manuscript. XZ contributed to the design of the study and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Shi J, Qu YP and Hou P: Pathogenetic mechanisms in gastric cancer. *World J Gastroenterol* 20: 13804-13819, 2014.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68: 394-424, 2018.
- Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. *Lancet* 388: 2654-2664, 2016.
- In H, Solsky I, Palis B, Langdon-Embry M, Ajani J and Sano T: Validation of the 8th Edition of the AJCC TNM staging system for gastric cancer using the national cancer database. *Ann Surg Oncol* 24: 3683-3691, 2017.
- Peng H, Deng Y, Wang L, Cheng Y, Xu Y, Liao J and Wu H: Identification of potential biomarkers with diagnostic value in pituitary adenomas using prediction analysis for microarrays method. *J Mol Neurosci* 69: 399-410, 2019.
- Wu Y, Jamal M, Xie T, Sun J, Song T, Yin Q, Li J, Pan S, Zeng X, Xie S and Zhang Q: Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer. *Cancer Sci* 110: 2734-2747, 2019.
- Chen Z, Zhou Y, Luo R, Liu K and Chen Z: Trophinin-associated protein expression is an independent prognostic biomarker in lung adenocarcinoma. *J Thorac Dis* 11: 2043-2050, 2019.
- Li D, Lin C, Li N, Du Y, Yang C, Bai Y, Feng Z, Su C, Wu R, Song S, *et al*: PLAGL2 and POFUT1 are regulated by an evolutionarily conserved bidirectional promoter and are collaboratively involved in colorectal cancer by maintaining stemness. *EBioMedicine* 45: 124-138, 2019.
- Yong L, YuFeng Z and Guang B: Association between PPP2CA expression and colorectal cancer prognosis tumor marker prognostic study. *Int J Surg* 59: 80-89, 2018.
- Troiano G, Guida A, Aquino G, Botti G, Losito NS, Papagerakis S, Pedicillo MC, Ionna F, Longo F, Cantile M, *et al*: Integrative histologic and bioinformatics analysis of BIRC5/Survivin expression in oral squamous cell carcinoma. *Int J Mol Sci* 19: E2664, 2018.
- D'Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, Calcagnile A, Sera F, Saieva C, Ottini L, Palli D, *et al*: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. *Eur J Cancer* 45: 461-469, 2009.
- Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, Yan DW, Tang HM and Peng ZH: Upregulated *INHBA* expression is associated with poor survival in gastric cancer. *Med Oncol* 29: 77-83, 2012.
- Li L, Zhu Z, Zhao Y, Zhang Q, Wu X, Miao B, Cao J and Fei S: *FN1*, *SPARC*, and *SERPINE1* are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics. *Sci Rep* 9: 7827, 2019.
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, *et al*: Gene ontology: Tool for the unification of biology. The gene ontology consortium. *Nat Genet* 25: 25-29, 2000.
- The Gene Ontology Consortium: The Gene Ontology Resource: 20 years and still GOing strong. *Nucleic Acids Res* 47: D330-D338, 2019.

16. Kanehisa M: 'Post-genome Informatics', Oxford University Press (2000). <https://www.kanehisa.jp/docs/archive/PGLI-contents.html>
17. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4: 44-57, 2009.
18. Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 37: 1-13, 2009.
19. Xu W, Wang Y, Wang Y, Lv S, Xu X and Dong X: Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer. *Int J Mol Med* 44: 390-404, 2019.
20. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, *et al*: STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 47: D607-D613, 2019.
21. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res* 13: 2498-2504, 2003.
22. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and Lin CY: cytoHubba: Identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 8 (Suppl 4): S11, 2014.
23. Liu Y, Cui S, Li W, Zhao Y, Yan X and Xu J: PAX3 is a biomarker and prognostic factor in melanoma: Database mining. *Oncol Lett* 17: 4985-4993, 2019.
24. Nagy Á, Lánckzy A, Menyhárt O and Györfy B: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. *Sci Rep* 8: 9227, 2018.
25. Rausei S, Ruspi L, Galli F, Pappalardo V, Di Rocco G, Martignoni F, Frattini F, Rovera F, Boni L and Dionigi G: Seventh tumor-node-metastasis staging of gastric cancer: Five-year follow-up. *World J Gastroenterol* 22: 7748-7753, 2016.
26. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, Li R, Chan AS, Law S, Troyanskaya OG, Wong J, *et al*: Variation in gene expression patterns in human gastric cancers. *Mol Biol Cell* 14: 3208-3215, 2003.
27. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, *et al*: Gene expression signature-based prognostic risk score in gastric cancer. *Clin Cancer Res* 17: 1850-1857, 2011.
28. Cui J, Chen Y, Chou WC, Sun L, Chen L, Suo J, Ni Z, Zhang M, Kong X, Hoffman LL, *et al*: An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. *Nucleic Acids Res* 39: 1197-207, 2011.
29. Serra O, Galán M, Ginesta MM, Calvo M, Sala N and Salazar R: Comparison and applicability of molecular classifications for gastric cancer. *Cancer Treat Rev* 77: 29-34, 2019.
30. Gilkes DM, Semenza GL and Wirtz D: Hypoxia and the extracellular matrix: Drivers of tumour metastasis. *Nat Rev Cancer* 14: 430-439, 2014.
31. Climent M, Pera M, Aymar I, Ramón JM, Grande L and Nogués X: Bone health in long-term gastric cancer survivors: A prospective study of high-dose vitamin D supplementation using an easy administration scheme. *J Bone Miner Metab* 36: 462-469, 2018.
32. Zhou ZH, Ji CD, Xiao HL, Zhao HB, Cui YH and Bian XW: Reorganized collagen in the tumor microenvironment of gastric cancer and its association with prognosis. *J Cancer* 8: 1466-1476, 2017.
33. Jang M, Koh I, Lee SJ, Cheong JH and Kim P: Droplet-based microtumor model to assess cell-ECM interactions and drug resistance of gastric cancer cells. *Sci Rep* 7: 41541, 2017.
34. Liu X and Chu KM: E-cadherin and gastric cancer: Cause, consequence, and applications. *Biomed Res Int* 2014: 637308, 2014.
35. Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, *et al*: Platelet-derived growth factor receptor- α regulates proliferation of gastrointestinal stromal tumor cells with mutations in KIT by stabilizing ETV1. *Gastroenterology* 149: 420-432.e16, 2015.
36. Rahbari NN, Kedrin D, Incio J, Liu H, Ho WW, Nia HT, Edrich CM, Jung K, Daubriac J, Chen I, *et al*: Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. *Sci Transl Med* 8: 360ra135, 2016.
37. Andersen MK, Rise K, Giskeødegård GF, Richardsen E, Bertilsson H, Størkersen Ø, Bathen TF, Rye M and Tessem MB: Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma. *Sci Rep* 8: 14269, 2018.
38. Bao Y, Wang L, Shi L, Yun F, Liu X, Chen Y, Chen C, Ren Y and Jia Y: Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer. *Cell Mol Biol Lett* 24: 38, 2019.
39. Zhu H, Chen H, Wang J, Zhou L and Liu S: Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer. *Oncotargets Ther* 12: 3441-3457, 2019.
40. Jin GH, Xu W, Shi Y and Wang LB: Celecoxib exhibits an anti-gastric cancer effect by targeting focal adhesion and leukocyte transendothelial migration-associated genes. *Oncol Lett* 12: 2345-2350, 2016.
41. He WQ, Gu JW, Li CY, Kuang YQ, Kong B, Cheng L, Zhang JH, Cheng JM and Ma Y: The PPI network and clusters analysis in glioblastoma. *Eur Rev Med Pharmacol Sci* 19: 4784-4790, 2015.
42. Miryala SK, Anbarasu A and Ramaiah S: Discerning molecular interactions: A comprehensive review on biomolecular interaction databases and network analysis tools. *Gene* 642: 84-94, 2018.
43. Yan H, Zheng G, Qu J, Liu Y, Huang X, Zhang E and Cai Z: Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis. *J Cell Physiol* 234: 23785-23797, 2019.
44. Zhang H, Sun Z, Li Y, Fan D and Jiang H: MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells. *Biomed Pharmacother* 88: 285-292, 2017.
45. Kun-Peng Z, Chun-Lin Z, Xiao-Long M and Lei Z: Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells. *J Cell Physiol* 234: 6927-6939, 2019.
46. Liao YX, Zhang ZP, Zhao J and Liu JP: Effects of fibronectin 1 on cell proliferation, senescence and apoptosis of human glioma cells through the PI3K/AKT signaling pathway. *Cell Physiol Biochem* 48: 1382-1396, 2018.
47. Cai X, Liu C, Zhang TN, Zhu YW, Dong X and Xue P: Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. *J Cell Biochem* 119: 4717-4728, 2018.
48. Yan P, He Y, Xie K, Kong S and Zhao W: In silico analyses for potential key genes associated with gastric cancer. *PeerJ* 6: e6092, 2018.
49. Jiang K, Liu H, Xie D and Xiao Q: Differentially expressed genes ASPN, COL1A1, FN1, VCAN and MUC5AC are potential prognostic biomarkers for gastric cancer. *Oncol Lett* 17: 3191-3202, 2019.
50. Sun S, Wang Y, Wu Y, Gao Y, Li Q, Abdulrahman AA, Liu XF, Ji GQ, Gao J, Li L, *et al*: Identification of COL1A1 as an invasion-related gene in malignant astrocytoma. *Int J Oncol* 53: 2542-2554, 2018.
51. Liu J, Shen JX, Wu HT, Li XL, Wen XF, Du CW and Zhang GJ: Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. *Discov Med* 25: 211-223, 2018.
52. Huang C, Yang X, Han L, Fan Z, Liu B, Zhang C and Lu T: The prognostic potential of alpha-1 type I collagen expression in papillary thyroid cancer. *Biochem Biophys Res Commun* 515: 125-132, 2019.
53. Zhang QN, Zhu HL, Xia MT, Liao J, Huang XT, Xiao JW and Yuan C: A panel of collagen genes are associated with prognosis of patients with gastric cancer and regulated by microRNA-29c-3p: An integrated bioinformatics analysis and experimental validation. *Cancer Manag Res* 11: 4757-4772, 2019.
54. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, *et al*: Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. *Neoplasia* 11: 388-396, 2009.
55. Yang H, Wu J, Zhang J, Yang Z, Jin W, Li Y, Jin L, Yin L, Liu H and Wang Z: Integrated bioinformatics analysis of key genes involved in progress of colon cancer. *Mol Genet Genomic Med* 7: e00588, 2019.
56. Chen ZL, Qin L, Peng XB, Hu Y and Liu B: INHBA gene silencing inhibits gastric cancer cell migration and invasion by impeding activation of the TGF- β signaling pathway. *J Cell Physiol* 234: 18065-18074, 2019.
57. Katayama Y, Oshima T, Sakamaki K, Aoyama T, Sato T, Masudo K, Shiozawa M, Yoshikawa T, Rino Y, Imada T and Masuda M: Clinical significance of INHBA gene expression in patients with gastric cancer who receive curative resection followed by adjuvant S-1 chemotherapy. *In Vivo* 31: 565-571, 2017.

58. Dai DN, Li Y, Chen B, Du Y, Li SB, Lu SX, Zhao ZP, Zhou AJ, Xue N, Xia TL, *et al*: Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis. *J Mol Med (Berl)* 95: 873-886, 2017.
59. Tian A, Pu K, Li B, Li M, Liu X, Gao L and Mao X: Weighted gene coexpression network analysis reveals hub genes involved in cholangiocarcinoma progression and prognosis. *Hepatol Res* 49: 1195-1206, 2019.
60. Kim J, Bae DH, Kim JH, Song KS, Kim YS and Kim SY: HOXC10 overexpression promotes cell proliferation and migration in gastric cancer. *Oncol Rep* 42: 202-212, 2019.
61. Jiang J, Liu HL, Tao L, Lin XY, Yang YD, Tan SW and Wu B: Let-7d inhibits colorectal cancer cell proliferation through the CST1/p65 pathway. *Int J Oncol* 53: 781-790, 2018.
62. Oh SS, Park S, Lee KW, Madhi H, Park SG, Lee HG, Cho YY, Yoo J and Dong Kim K: Extracellular cystatin SN and cathepsin B prevent cellular senescence by inhibiting abnormal glycogen accumulation. *Cell Death Dis* 8: e2729, 2017.
63. Lin S, Lin B, Wang X, Pan Y, Xu Q, He JS, Gong W, Xing R, He Y, Guo L, *et al*: Silencing of ATP4B of ATPase H⁺/K⁺ transporting beta subunit by intragenic epigenetic alteration in human gastric cancer cells. *Oncol Res* 25: 317-329, 2017.
64. Fei HJ, Chen SC, Zhang JY, Li SY, Zhang LL, Chen YY, Chang CX and Xu CM: Identification of significant biomarkers and pathways associated with gastric carcinogenesis by whole genome-wide expression profiling analysis. *Int J Oncol* 52: 955-966, 2018.
65. Lozano-Pope I, Sharma A, Matthias M, Doran KS and Obonyo M: Effect of myeloid differentiation primary response gene 88 on expression profiles of genes during the development and progression of *Helicobacter*-induced gastric cancer. *BMC Cancer* 17: 133, 2017.
66. Di Mario F and Goni E: Gastric acid secretion: Changes during a century. *Best Pract Res Clin Gastroenterol* 28: 953-65, 2014.
67. Saha A, Hammond CE, Beeson C, Peek RM Jr and Smolka AJ: *Helicobacter pylori* represses proton pump expression and inhibits acid secretion in human gastric mucosa. *Gut* 59: 874-881, 2010.
68. Friis-Hansen L: Achlorhydria is associated with gastric microbial overgrowth and development of cancer: Lessons learned from the gastrin knockout mouse. *Scand J Clin Lab Invest* 66: 607-621, 2006.
69. Sáenz JB and Mills JC: Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer. *Nat Rev Gastroenterol Hepatol* 15: 257-273, 2018.
70. Vinasco K, Mitchell HM, Kaakoush NO and Castaño-Rodríguez N: Microbial carcinogenesis: Lactic acid bacteria in gastric cancer. *Biochim Biophys Acta Rev Cancer* 1872: 188309, 2019.
71. Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC and Figueiredo C: Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. *Gut* 67: 226-236, 2018.
72. Wang LL, Liu JX, Yu XJ, Si JL, Zhai YX and Dong QJ: Microbial community reshaped in gastric cancer. *Eur Rev Med Pharmacol Sci* 22: 7257-7264, 2018.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.